首页 > 最新文献

Human Vaccines & Immunotherapeutics最新文献

英文 中文
Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-24 DOI: 10.1080/21645515.2025.2463194
Federico Martinon-Torres, Erik Lamberth, Silvina Natalini Martinez, Ignacio Salamanca de la Cueva, Lefteris Zolotas, Islamiat Oladipupo, Jason D Maguire, James Trammel, Robert O'Neill, Paul A Liberator, Paula Peyrani, Luis Jodar, William C Gruber, Annaliesa S Anderson, Johannes Beeslaar

Invasive meningococcal disease is an uncommon but serious disease predominantly affecting children. This phase 2b study evaluated MenABCWY in 6-month-old infants followed by MenB-fHbp and MenABCWY in 2-month-old infants, the latter being the target age and intervention. Participants were randomized to MenABCWY, 60 µg or 120 µg MenB-fHbp+MenACWY-TT, or 4CMenB+MenACWY-TT, administered as 2 primary and 1 booster dose. The primary safety objective was to describe the safety profile of MenABCWY in participants enrolled at 2 months. Primary immunogenicity objectives were the percentage of participants achieving seroprotective serum bactericidal antibody using human complement titers. Overall, 314 and 12 participants were randomized to sentinel cohort and open-label expanded-enrollment stages, respectively. Based on 2 reports of fever requiring invasive investigations and accompanied by cerebrospinal fluid pleocytosis and 1 report arising from a previous study, the Sponsor terminated the study. Local reactions and systemic events after primary vaccination were generally mild to moderate, and tended to be higher with MenABCWY versus 4CMenB+MenACWY-TT. Immunogenicity data suggest that 1 month after vaccination 2, MenABCWY responses for MenA/C/W/Y were robust and comparable with 4CMenB+MenACWY-TT in 2-month-old participants. Immune responses for MenB test strains were higher with MenABCWY versus 4CMenB+MenACWY-TT and generally similar with 60 µg and 120 µg MenB-fHbp+MenACWY-TT or MenABCWY. Based on the limited results, the consistency of MenB immune responses with 60 µg and 120 µg MenB-fHbp suggests doses < 60 µg could be investigated to assess whether a more acceptable safety profile in conjunction with beneficial immune responses is possible in 2-month-old infants.

{"title":"Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.","authors":"Federico Martinon-Torres, Erik Lamberth, Silvina Natalini Martinez, Ignacio Salamanca de la Cueva, Lefteris Zolotas, Islamiat Oladipupo, Jason D Maguire, James Trammel, Robert O'Neill, Paul A Liberator, Paula Peyrani, Luis Jodar, William C Gruber, Annaliesa S Anderson, Johannes Beeslaar","doi":"10.1080/21645515.2025.2463194","DOIUrl":"10.1080/21645515.2025.2463194","url":null,"abstract":"<p><p>Invasive meningococcal disease is an uncommon but serious disease predominantly affecting children. This phase 2b study evaluated MenABCWY in 6-month-old infants followed by MenB-fHbp and MenABCWY in 2-month-old infants, the latter being the target age and intervention. Participants were randomized to MenABCWY, 60 µg or 120 µg MenB-fHbp+MenACWY-TT, or 4CMenB+MenACWY-TT, administered as 2 primary and 1 booster dose. The primary safety objective was to describe the safety profile of MenABCWY in participants enrolled at 2 months. Primary immunogenicity objectives were the percentage of participants achieving seroprotective serum bactericidal antibody using human complement titers. Overall, 314 and 12 participants were randomized to sentinel cohort and open-label expanded-enrollment stages, respectively. Based on 2 reports of fever requiring invasive investigations and accompanied by cerebrospinal fluid pleocytosis and 1 report arising from a previous study, the Sponsor terminated the study. Local reactions and systemic events after primary vaccination were generally mild to moderate, and tended to be higher with MenABCWY versus 4CMenB+MenACWY-TT. Immunogenicity data suggest that 1 month after vaccination 2, MenABCWY responses for MenA/C/W/Y were robust and comparable with 4CMenB+MenACWY-TT in 2-month-old participants. Immune responses for MenB test strains were higher with MenABCWY versus 4CMenB+MenACWY-TT and generally similar with 60 µg and 120 µg MenB-fHbp+MenACWY-TT or MenABCWY. Based on the limited results, the consistency of MenB immune responses with 60 µg and 120 µg MenB-fHbp suggests doses < 60 µg could be investigated to assess whether a more acceptable safety profile in conjunction with beneficial immune responses is possible in 2-month-old infants.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2463194"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global research trends of immunosenescence and immunotherapy: A bibliometric study.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-24 DOI: 10.1080/21645515.2025.2469403
Wendi Li, Lin Xiao, Haiyang Li, Wei Cui

Immunosenescence refers to the gradual decline in immune system function with age, increasing susceptibility to infections and cancer in the elderly. The advent of novel immunotherapies has revolutionized the field of cancer treatment. However, the majority of patients exhibit poor re-sponses to immunotherapy, with immunosenescence likely playing a significant role. In recent years, significant progress has been made in understanding the interplay between immunosenescence and immunotherapy. Our research aims to explore the prospects and development trends in the field of immunosenescence and immunotherapy using a bibliometric analysis. Relevant articles were collected from the Web of Science Core Collection (WoSCC) (retrieved on July 20, 2024). Primary bibliometric characteristics were analyzed using the R package "Biblio-metrix," and keyword co-occurrence analysis and visualization were conducted using VOSviewer. A total of 213 English-language original research and review articles spanning 35 years were re-trieved for bibliometric analysis. There was a surge in publications in this field starting in 2017. The United States and China contributed the most articles. Frontiers in Immunology was the most productive journal, while the University of California System was the highest contributing institution. Besse Benjamin from France emerged as the most influential researcher in this field. Popular keywords included "nivolumab," "T cells," "dendritic cells," and "regulatory T cells." The "immunosenescence-associated secretory phenotype" has become a new hotspot, with immune checkpoint inhibitors remaining a central theme in this domain. The field of immunosenescence and immunotherapy is entering a phase of rapid development and will continue to hold significant value in future research.

{"title":"Global research trends of immunosenescence and immunotherapy: A bibliometric study.","authors":"Wendi Li, Lin Xiao, Haiyang Li, Wei Cui","doi":"10.1080/21645515.2025.2469403","DOIUrl":"10.1080/21645515.2025.2469403","url":null,"abstract":"<p><p>Immunosenescence refers to the gradual decline in immune system function with age, increasing susceptibility to infections and cancer in the elderly. The advent of novel immunotherapies has revolutionized the field of cancer treatment. However, the majority of patients exhibit poor re-sponses to immunotherapy, with immunosenescence likely playing a significant role. In recent years, significant progress has been made in understanding the interplay between immunosenescence and immunotherapy. Our research aims to explore the prospects and development trends in the field of immunosenescence and immunotherapy using a bibliometric analysis. Relevant articles were collected from the Web of Science Core Collection (WoSCC) (retrieved on July 20, 2024). Primary bibliometric characteristics were analyzed using the R package \"Biblio-metrix,\" and keyword co-occurrence analysis and visualization were conducted using VOSviewer. A total of 213 English-language original research and review articles spanning 35 years were re-trieved for bibliometric analysis. There was a surge in publications in this field starting in 2017. The United States and China contributed the most articles. Frontiers in Immunology was the most productive journal, while the University of California System was the highest contributing institution. Besse Benjamin from France emerged as the most influential researcher in this field. Popular keywords included \"nivolumab,\" \"T cells,\" \"dendritic cells,\" and \"regulatory T cells.\" The \"immunosenescence-associated secretory phenotype\" has become a new hotspot, with immune checkpoint inhibitors remaining a central theme in this domain. The field of immunosenescence and immunotherapy is entering a phase of rapid development and will continue to hold significant value in future research.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2469403"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-25 DOI: 10.1080/21645515.2025.2461844
Priya Dhawale, Sanket Shah, Kaushal Sharma, Deepa Sikriwal, Varnik Kumar, Arnabjyoti Bhagawati, Sakshi Dhar, Pratiksha Shetty, Syed Ahmed

S. pneumoniae serotypes responsible for pneumococcal disease differ with respect to disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and with time. Although PCVs have blunted the pneumococcal disease burden, they are plagued with numerous challenges, especially the emergence of NVTs. In this review, we show that there are diverse serotypes, especially NVTs, responsible for causing pneumococcal diseases in LMICs of South Asia across different studies conducted between 2012 and 2024. We propose that pharmaceutical/biotech companies should tailor/customize the PCVs as per the region-specific serotype prevalence based on surveillance data. Furthermore, protein-based vaccines, or WCVs, have been explored and can serve as viable alternatives to address the limitations associated with PCVs. However, robust studies are warranted in different geographies to demonstrate its efficacy and safety in clinical trials as well as the real-world effectiveness of these promising candidates.

{"title":"<i>Streptococcus pneumoniae</i> serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?","authors":"Priya Dhawale, Sanket Shah, Kaushal Sharma, Deepa Sikriwal, Varnik Kumar, Arnabjyoti Bhagawati, Sakshi Dhar, Pratiksha Shetty, Syed Ahmed","doi":"10.1080/21645515.2025.2461844","DOIUrl":"10.1080/21645515.2025.2461844","url":null,"abstract":"<p><p><i>S. pneumoniae</i> serotypes responsible for pneumococcal disease differ with respect to disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and with time. Although PCVs have blunted the pneumococcal disease burden, they are plagued with numerous challenges, especially the emergence of NVTs. In this review, we show that there are diverse serotypes, especially NVTs, responsible for causing pneumococcal diseases in LMICs of South Asia across different studies conducted between 2012 and 2024. We propose that pharmaceutical/biotech companies should tailor/customize the PCVs as per the region-specific serotype prevalence based on surveillance data. Furthermore, protein-based vaccines, or WCVs, have been explored and can serve as viable alternatives to address the limitations associated with PCVs. However, robust studies are warranted in different geographies to demonstrate its efficacy and safety in clinical trials as well as the real-world effectiveness of these promising candidates.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2461844"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient preferences toward herpes zoster vaccination among individuals aged 50 years or older in South Korea: Findings from a discrete choice experiment.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-03-10 DOI: 10.1080/21645515.2025.2469419
Sumitra Shantakumar, Eun Ju Choo, Raunak Parikh, Taeyeon Kwon, Hyungwoo Kim, Lawrence Vandervoort, Vince Grillo, Jacob Lee

In South Korea, the increasing incidence of herpes zoster (HZ) and aging population warrant consideration of HZ vaccination for older adults. There is a need to understand the HZ vaccine-related preferences of adults aged ≥50 years and adult children (working or financially independent adults contributing to healthcare decision-making for their parents aged ≥50 years). A discrete choice experiment was conducted to elicit HZ vaccine preferences of the HZ-naïve general public aged ≥50 years (n = 500), current/former HZ patients aged ≥50 years (n = 150), and adult children (n = 150). An online questionnaire was administered through March-May 2023; for each preference-elicitation question, respondents selected between three hypothetical HZ vaccine profiles, characterized by five attributes with varying levels, or "no vaccine". Respondents generally accepted an increased number of doses (from one to two) for a longer protection duration (from ≥4 to ≥7 or ≥10 years). By mean relative importance (RI), protection duration (RI: 37.1%; 95% confidence interval [CI]: 36.0%, 38.1%), lifetime HZ risk reduction (27.3%; 95% CI: 26.3%, 28.4%) and short-term side effects (14.9%; 95% CI: 14.1%, 15.6%) had the strongest impact on respondents' HZ vaccine decision-making. Adult children viewed short-term side effects with significantly greater RI than the general public and current/former HZ patients (19.1%, 13.5%, 15.2%, respectively, p < .001). Respondents with selected comorbidities placed higher RI than those without comorbidities on protection duration (39.3% versus 34.2%, p < .001) and lower RI on prevention of HZ-related complications (8.7% versus 10.4%, p = .007). Findings may guide health policy design/refinement and physician-patient conversations on HZ vaccination/vaccines.

{"title":"Patient preferences toward herpes zoster vaccination among individuals aged 50 years or older in South Korea: Findings from a discrete choice experiment.","authors":"Sumitra Shantakumar, Eun Ju Choo, Raunak Parikh, Taeyeon Kwon, Hyungwoo Kim, Lawrence Vandervoort, Vince Grillo, Jacob Lee","doi":"10.1080/21645515.2025.2469419","DOIUrl":"10.1080/21645515.2025.2469419","url":null,"abstract":"<p><p>In South Korea, the increasing incidence of herpes zoster (HZ) and aging population warrant consideration of HZ vaccination for older adults. There is a need to understand the HZ vaccine-related preferences of adults aged ≥50 years and adult children (working or financially independent adults contributing to healthcare decision-making for their parents aged ≥50 years). A discrete choice experiment was conducted to elicit HZ vaccine preferences of the HZ-naïve general public aged ≥50 years (<i>n</i> = 500), current/former HZ patients aged ≥50 years (<i>n</i> = 150), and adult children (<i>n</i> = 150). An online questionnaire was administered through March-May 2023; for each preference-elicitation question, respondents selected between three hypothetical HZ vaccine profiles, characterized by five attributes with varying levels, or \"no vaccine\". Respondents generally accepted an increased number of doses (from one to two) for a longer protection duration (from ≥4 to ≥7 or ≥10 years). By mean relative importance (RI), protection duration (RI: 37.1%; 95% confidence interval [CI]: 36.0%, 38.1%), lifetime HZ risk reduction (27.3%; 95% CI: 26.3%, 28.4%) and short-term side effects (14.9%; 95% CI: 14.1%, 15.6%) had the strongest impact on respondents' HZ vaccine decision-making. Adult children viewed short-term side effects with significantly greater RI than the general public and current/former HZ patients (19.1%, 13.5%, 15.2%, respectively, <i>p</i> < .001). Respondents with selected comorbidities placed higher RI than those without comorbidities on protection duration (39.3% versus 34.2%, <i>p</i> < .001) and lower RI on prevention of HZ-related complications (8.7% versus 10.4%, <i>p</i> = .007). Findings may guide health policy design/refinement and physician-patient conversations on HZ vaccination/vaccines.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2469419"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A narrative review on the effectiveness of PPSV23 vaccination in adults in China.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-03-18 DOI: 10.1080/21645515.2024.2440955
Weiyan Zhang, Peng Bai, Weijun Hu

Pneumococcal Polysaccharide Vaccine (PPSV23) is available for free in some Chinese cities for elderly patients and those with comorbidities. However, there is a lack of studies summarizing its preventive effect specifically in Chinese adults. This review aims to discuss the epidemiology of pneumococcal disease, coverage and effectiveness of PPSV23 vaccination, elderly individuals and patients with comorbidities, coadministration of PPSV23 vaccine with other vaccines, and future directions for its use in China. It was found that the PPSV23 vaccination rate among the elderly ranged from 1.2% to 42.1% depending on location, with an effectiveness of 9.34%(95%CI: 2.05%, 16.62%) to 57.7%(95%CI: 20.7%, 77.5%). There is a need to raise awareness of pneumococcal disease and its prevention, especially in China. To better manage pneumococcal disease in China, developing new vaccines for common serotypes and continuously monitoring serotype distribution associated with the disease is also needed.

{"title":"A narrative review on the effectiveness of PPSV23 vaccination in adults in China.","authors":"Weiyan Zhang, Peng Bai, Weijun Hu","doi":"10.1080/21645515.2024.2440955","DOIUrl":"https://doi.org/10.1080/21645515.2024.2440955","url":null,"abstract":"<p><p>Pneumococcal Polysaccharide Vaccine (PPSV23) is available for free in some Chinese cities for elderly patients and those with comorbidities. However, there is a lack of studies summarizing its preventive effect specifically in Chinese adults. This review aims to discuss the epidemiology of pneumococcal disease, coverage and effectiveness of PPSV23 vaccination, elderly individuals and patients with comorbidities, coadministration of PPSV23 vaccine with other vaccines, and future directions for its use in China. It was found that the PPSV23 vaccination rate among the elderly ranged from 1.2% to 42.1% depending on location, with an effectiveness of 9.34%(95%CI: 2.05%, 16.62%) to 57.7%(95%CI: 20.7%, 77.5%). There is a need to raise awareness of pneumococcal disease and its prevention, especially in China. To better manage pneumococcal disease in China, developing new vaccines for common serotypes and continuously monitoring serotype distribution associated with the disease is also needed.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440955"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meningococcal vaccination disparities in the United States (2010-2021): Findings from the National Immunization Survey-Teen and a commercial insurance database.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-03-19 DOI: 10.1080/21645515.2025.2479338
Oscar Herrera-Restrepo, Marta Kwiatkowska, Samuel Huse, Nelson Ndegwa, Zeki Kocaata, Michael L Ganz

In the United States, while meningococcal vaccines are available and recommended for adolescents and young adults, coverage remains low and disparities persist. We evaluated meningococcal serogroups A, C, W, Y (MenACWY) and B (MenB) vaccine uptake, completion, and compliance using a cross-sectional analysis of National Immunization Survey-Teen (NIS-Teen) data (2015-2021) and a cohort analysis of commercial claims data (2010-2021). Regression models were used to identify factors associated with vaccine uptake. Included in the NIS-Teen MenACWY and MenB analyses were 138,952 and 177,077 patients, respectively. Included in the claims MenACWY and MenB analyses were 953,905 and 818,424 patients, respectively. In 2021, MenACWY uptake was 86.4% (95% confidence interval [CI]: 83.6-88.8%) among ≤13-year-olds (NIS-Teen) and 63.2% (62.8-63.5%) among 11-12-year-olds (claims). MenB was 33.7% (30.5-37.1%) among ≤17-year-olds (NIS-Teen), 41.6% (41.2-42.0%) among 16-18-year-olds (claims), and 15.0% (14.7-15.4%) among 19-23-year-olds (claims). The states with the lowest and highest MenB uptake by ≤17-year-olds in 2021 (NIS-Teen) were Minnesota (10.1% [3.9-23.6%]) and North Dakota (69.9% [52.1-83.2%]). Factors associated with MenACWY uptake included living in a state with a vaccine mandate, Black or Hispanic race (versus White), and well-child visit attendance. Factors associated with MenB uptake included having Medicaid (versus private insurance) and Hispanic race (versus White). The findings suggest that meningococcal vaccination coverage disparities persist across vaccines, age, geography, and race and ethnicity. Higher MenACWY (versus MenB) coverage suggests the benefit of routine recommendations. Annual well-child visits and simplified vaccination schedules could reduce vaccination access barriers.

{"title":"Meningococcal vaccination disparities in the United States (2010-2021): Findings from the National Immunization Survey-Teen and a commercial insurance database.","authors":"Oscar Herrera-Restrepo, Marta Kwiatkowska, Samuel Huse, Nelson Ndegwa, Zeki Kocaata, Michael L Ganz","doi":"10.1080/21645515.2025.2479338","DOIUrl":"10.1080/21645515.2025.2479338","url":null,"abstract":"<p><p>In the United States, while meningococcal vaccines are available and recommended for adolescents and young adults, coverage remains low and disparities persist. We evaluated meningococcal serogroups A, C, W, Y (MenACWY) and B (MenB) vaccine uptake, completion, and compliance using a cross-sectional analysis of National Immunization Survey-Teen (NIS-Teen) data (2015-2021) and a cohort analysis of commercial claims data (2010-2021). Regression models were used to identify factors associated with vaccine uptake. Included in the NIS-Teen MenACWY and MenB analyses were 138,952 and 177,077 patients, respectively. Included in the claims MenACWY and MenB analyses were 953,905 and 818,424 patients, respectively. In 2021, MenACWY uptake was 86.4% (95% confidence interval [CI]: 83.6-88.8%) among ≤13-year-olds (NIS-Teen) and 63.2% (62.8-63.5%) among 11-12-year-olds (claims). MenB was 33.7% (30.5-37.1%) among ≤17-year-olds (NIS-Teen), 41.6% (41.2-42.0%) among 16-18-year-olds (claims), and 15.0% (14.7-15.4%) among 19-23-year-olds (claims). The states with the lowest and highest MenB uptake by ≤17-year-olds in 2021 (NIS-Teen) were Minnesota (10.1% [3.9-23.6%]) and North Dakota (69.9% [52.1-83.2%]). Factors associated with MenACWY uptake included living in a state with a vaccine mandate, Black or Hispanic race (versus White), and well-child visit attendance. Factors associated with MenB uptake included having Medicaid (versus private insurance) and Hispanic race (versus White). The findings suggest that meningococcal vaccination coverage disparities persist across vaccines, age, geography, and race and ethnicity. Higher MenACWY (versus MenB) coverage suggests the benefit of routine recommendations. Annual well-child visits and simplified vaccination schedules could reduce vaccination access barriers.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2479338"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of a multimedia campaign to increase human papillomavirus vaccine acceptance in Dhaka, Bangladesh. 孟加拉国达卡为提高人乳头瘤病毒疫苗接受度而开展的多媒体宣传活动的效果。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-08 DOI: 10.1080/21645515.2024.2447105
Sohail Agha, Sarah Francis, Drew Bernard, Aslam Fareed, Kasrina Azad, Firdausi Qadri

Increasing the uptake of Human Papillomavirus (HPV) vaccine among adolescent girls is a high priority for the government of Bangladesh. This study examines correlates of HPV vaccine adoption in Dhaka Division, the largest division in Bangladesh. The 18-day vaccination campaign was accompanied by multimedia messages. We use the Fogg Behavior Model (FBM) as the theoretical framework for our analysis. Using a survey instrument based on the FBM, we analyze cross-sectional data collected from 611 caregivers of girls aged 9-17 in Dhaka. Survey data was collected in November and December 2023. Caregivers were recruited via Facebook and Instagram ads and interviewed through the Facebook Messenger App. About one-third of caregivers reported that their child had been vaccinated. We conducted bivariate and multivariate analyses to assess the relationships between the caregivers' motivation, ability, exposure to the campaign and their child's vaccination status. Adjusted odds ratios from logistic regression analyses, suggest that caregivers' motivation, ability, and exposure to the multimedia campaign contributed to vaccine uptake. Caregivers' motivation to get their child vaccinated was high (74%) but their ability was low (20%). Exposure to campaign messages had a dose-response relationship with vaccine adoption. However, 48% of caregivers remained unexposed to the multimedia campaign. We discuss challenges that the government's HPV vaccination program is likely to face and identify program-related research questions that are important to answer for the success of future vaccination efforts.

在青春期女孩中增加人乳头瘤病毒(HPV)疫苗的吸收是孟加拉国政府的高度优先事项。本研究调查了孟加拉国最大的地区达卡地区HPV疫苗采用的相关因素。为期18天的疫苗接种活动伴随着多媒体信息。我们使用Fogg行为模型(FBM)作为我们分析的理论框架。使用基于FBM的调查工具,我们分析了从达卡611名9-17岁女孩的照顾者中收集的横断面数据。调查数据于2023年11月和12月收集。护理人员通过Facebook和Instagram广告招募,并通过Facebook Messenger应用程序进行采访。大约三分之一的护理人员报告说,他们的孩子已经接种了疫苗。我们进行了双变量和多变量分析,以评估照顾者的动机、能力、对运动的接触与孩子的疫苗接种状况之间的关系。从逻辑回归分析中调整的优势比表明,护理人员的动机、能力和对多媒体活动的接触有助于疫苗的吸收。照顾者让孩子接种疫苗的动机很高(74%),但他们的能力很低(20%)。接触运动信息与接种疫苗有剂量-反应关系。然而,48%的护理人员仍然没有接触到多媒体活动。我们讨论了政府的HPV疫苗接种计划可能面临的挑战,并确定了与计划相关的研究问题,这些问题对未来疫苗接种工作的成功至关重要。
{"title":"Effects of a multimedia campaign to increase human papillomavirus vaccine acceptance in Dhaka, Bangladesh.","authors":"Sohail Agha, Sarah Francis, Drew Bernard, Aslam Fareed, Kasrina Azad, Firdausi Qadri","doi":"10.1080/21645515.2024.2447105","DOIUrl":"10.1080/21645515.2024.2447105","url":null,"abstract":"<p><p>Increasing the uptake of Human Papillomavirus (HPV) vaccine among adolescent girls is a high priority for the government of Bangladesh. This study examines correlates of HPV vaccine adoption in Dhaka Division, the largest division in Bangladesh. The 18-day vaccination campaign was accompanied by multimedia messages. We use the Fogg Behavior Model (FBM) as the theoretical framework for our analysis. Using a survey instrument based on the FBM, we analyze cross-sectional data collected from 611 caregivers of girls aged 9-17 in Dhaka. Survey data was collected in November and December 2023. Caregivers were recruited via Facebook and Instagram ads and interviewed through the Facebook Messenger App. About one-third of caregivers reported that their child had been vaccinated. We conducted bivariate and multivariate analyses to assess the relationships between the caregivers' motivation, ability, exposure to the campaign and their child's vaccination status. Adjusted odds ratios from logistic regression analyses, suggest that caregivers' motivation, ability, and exposure to the multimedia campaign contributed to vaccine uptake. Caregivers' motivation to get their child vaccinated was high (74%) but their ability was low (20%). Exposure to campaign messages had a dose-response relationship with vaccine adoption. However, 48% of caregivers remained unexposed to the multimedia campaign. We discuss challenges that the government's HPV vaccination program is likely to face and identify program-related research questions that are important to answer for the success of future vaccination efforts.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2447105"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human vaccines and immunotherapeutics: News January 2025.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-10 DOI: 10.1080/21645515.2025.2463800
Ronald Ellis, Adam Weiss
{"title":"Human vaccines and immunotherapeutics: News January 2025.","authors":"Ronald Ellis, Adam Weiss","doi":"10.1080/21645515.2025.2463800","DOIUrl":"https://doi.org/10.1080/21645515.2025.2463800","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2463800"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Willingness to pay for vaccines in China: A systematic review and single-arm Bayesian meta-analysis.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-04 DOI: 10.1080/21645515.2025.2454076
Yi Li, Ziwei Liu, Liangru Zhou, Ruifeng Li

The effective implementation of vaccination heavily depends on the society's willingness to pay (WTP). There is currently a dearth of comprehensive evidence about WTP for vaccines in China. This systematic review aims to review studies on the WTP for vaccines, to summarize factors affect WTP in China. Base-case analysis and Sensitivity analysis of WTP for every vaccine were estimated via single-arm Bayesian meta-analysis. A total of 28 studies were included for systematic review. The point estimates and 95% Credible Interval of pooled WTP for influenza and HPV (9-valent) vaccine were $27.409 (23.230, 31.486), $464.707 (441.355, 489.456). Influencing factors to WTP were age, income, peer influence, health condition and etc. Future research should give focus to improving sample representativeness and survey tool, conducting intervention trials, identifying effective methods to promote WTP.

{"title":"Willingness to pay for vaccines in China: A systematic review and single-arm Bayesian meta-analysis.","authors":"Yi Li, Ziwei Liu, Liangru Zhou, Ruifeng Li","doi":"10.1080/21645515.2025.2454076","DOIUrl":"10.1080/21645515.2025.2454076","url":null,"abstract":"<p><p>The effective implementation of vaccination heavily depends on the society's willingness to pay (WTP). There is currently a dearth of comprehensive evidence about WTP for vaccines in China. This systematic review aims to review studies on the WTP for vaccines, to summarize factors affect WTP in China. Base-case analysis and Sensitivity analysis of WTP for every vaccine were estimated via single-arm Bayesian meta-analysis. A total of 28 studies were included for systematic review. The point estimates and 95% Credible Interval of pooled WTP for influenza and HPV (9-valent) vaccine were $27.409 (23.230, 31.486), $464.707 (441.355, 489.456). Influencing factors to WTP were age, income, peer influence, health condition and etc. Future research should give focus to improving sample representativeness and survey tool, conducting intervention trials, identifying effective methods to promote WTP.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454076"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profile of Chlamydia vaccine research: A bibliometric analysis. 衣原体疫苗研究概况:文献计量分析。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-05 DOI: 10.1080/21645515.2025.2459459
Xuemei Wang, Qian Wang, Yidan Gao, Lijuan Jiang, Lingli Tang

Vaccination is the most effective measure to prevent Chlamydia infection. However, to date, no vaccine has successfully completed the rigorous clinical trial process and gained regulatory approval for use in clinical practice. Scholars have been working on a safe and effective Chlamydia vaccine. In order to better grasp, the global frontiers and development trends in this field, a comprehensive bibliometric analysis was carried out. A total of 234 publications closely regarding Chlamydia vaccines were culled from the Web of Science Core Collection database, and the bibliometric information was then extracted with CiteSpace and VOSviewer software. After measurement analysis, the most influential papers were identified in this area, including highly cited papers, references with strong citation burst, and high co-citated papers. Vaccine has published the most literature on Chlamydia vaccines. Only scholars from 39 countries/regions have been engaged in studying Chlamydia vaccines. The USA is the most prolific country and has the highest collaborative strength. The current research area has focused on protective immunity and immunopathological response. Major outer membrane protein (MOMP) is the most common target vaccine antigen. This study reveals the status of literature and highlights emerging trends in this field, which helps researchers seek insights into this area and serve as a reference guide for further investigations.

{"title":"Profile of <i>Chlamydia</i> vaccine research: A bibliometric analysis.","authors":"Xuemei Wang, Qian Wang, Yidan Gao, Lijuan Jiang, Lingli Tang","doi":"10.1080/21645515.2025.2459459","DOIUrl":"10.1080/21645515.2025.2459459","url":null,"abstract":"<p><p>Vaccination is the most effective measure to prevent <i>Chlamydia</i> infection. However, to date, no vaccine has successfully completed the rigorous clinical trial process and gained regulatory approval for use in clinical practice. Scholars have been working on a safe and effective <i>Chlamydia</i> vaccine. In order to better grasp, the global frontiers and development trends in this field, a comprehensive bibliometric analysis was carried out. A total of 234 publications closely regarding <i>Chlamydia</i> vaccines were culled from the Web of Science Core Collection database, and the bibliometric information was then extracted with CiteSpace and VOSviewer software. After measurement analysis, the most influential papers were identified in this area, including highly cited papers, references with strong citation burst, and high co-citated papers. <i>Vaccine</i> has published the most literature on <i>Chlamydia</i> vaccines. Only scholars from 39 countries/regions have been engaged in studying <i>Chlamydia</i> vaccines. The USA is the most prolific country and has the highest collaborative strength. The current research area has focused on protective immunity and immunopathological response. Major outer membrane protein (MOMP) is the most common target vaccine antigen. This study reveals the status of literature and highlights emerging trends in this field, which helps researchers seek insights into this area and serve as a reference guide for further investigations.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2459459"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Vaccines & Immunotherapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1